$BIAFJul 7, 2026, 12:46 PMAI processed
BIAF: Q2 CyPath Lung volumes >200% YoY and +30% QoQ as physician adoption grows
AI Summary
BioAffinity (BIAF / BIAFW) reported Q2 2026 CyPath Lung test volume rose more than 200% year‐over‐year and roughly 30% quarter‐over‐quarter, driven by higher utilization among existing clients and a 155% increase in physician offices ordering the test; the company has performed nearly 3,000 CyPath Lung tests since commercial launch. CyPath Lung is marketed as a CLIA LDT that uses flow cytometry and AI—a published trial in high‐risk patients showed 92% sensitivity, 87% specificity and a 99% negative predictive value for nodules <20 mm, which the company says can help spare unnecessary invasive procedures; company will report Q2 financials in August.
Positives
- Q2 CyPath Lung test volume >200% year‑over‑year and ~30% quarter‑over‑quarter
- 155% increase in physician offices ordering CyPath Lung versus Q2 2025
- Nearly 3,000 CyPath Lung tests performed since commercial launch; published trial reported 92% sensitivity, 87% specificity and 99% NPV for nodules <20 mm
Negatives
- CyPath Lung is marketed as a Laboratory Developed Test (LDT), not an FDA‑cleared diagnostic, and should be used alongside other clinical findings
- Company released commercial volume metrics but has not yet reported Q2 financial results (expected in August)
- Forward‑looking statements note regulatory risk for LDTs and other commercialization uncertainties